// App-Quantinova.ai

5515 : Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.

Researchers

Presenter

  • Cara Amanda Mathews

Principal Investigators

  • Fiona Simpkins

  • Karen Anne Cadoo

  • Ying L Liu

  • Diane M. Provencher

  • Colleen McCormick

  • Adam ElNaggar

  • Alon D Altman

  • Lucy Gilbert

  • Destin Black

  • Nashwa Kabil

  • James Bennett

  • Jiefen Munley

  • Judy Yu

  • Carol Aghajanian

Medical Centers

  • Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI

  • Department of Obstetrics and Gynecology, Jordan Center for Gynecologic Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Centre Hospitalier de l'Université de Montréal (CHUM), Division of Gynecologic Oncology, Montréal, QC

  • Canada.

  • Legacy Gyencologic Oncology, Portland, OR

  • West Cancer Center and Research Institute., Memphis, TN

  • CancerCare Manitoba, Research Institute of Oncology and Hematology, University of Manitoba, Winnipeg, MB

  • Division of Gynecologic Oncology, McGill University Health Centre, Montreal, QC

  • Willis-Knighton Cancer Center, Shreveport, LA

  • AstraZeneca, Gaithersburg, MD

  • AstraZeneca, Wilmington, DE

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • BRCA mutation

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02983799

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved